Replimune Group Ownership | Who Owns Replimune Group?

Overview ForecastFinancials Chart Transcripts

Replimune Group Ownership Summary

Replimune Group is owned by 11.39% institutional investors, 2.72% insiders, and 85.89% retail investors. Baker bros. advisors lp is the largest institutional shareholder, holding 11.98% of REPL shares. US Small-Cap Growth II Equity Comp is the top mutual fund, with 2.92% of its assets in Replimune Group shares.

REPL Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Replimune Group	11.39%	2.72%	85.89%
Sector	Healthcare Stocks	35.58%	11.87%	52.55%
Industry	Biotech Stocks	35.75%	11.83%	52.41%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Baker bros. advisors lp	11.05M	11.98%	$84.50M
Price t rowe associates inc /md/	8.12M	8.81%	$62.13M
Rtw investments, lp	7.36M	7.98%	$56.28M
Blackrock	4.71M	7.08%	$42.42M
Blackrock funding, inc. /de	6.24M	6.77%	$47.73M
Suvretta capital management	4.22M	4.58%	$32.30M
State street	3.78M	4.10%	$28.93M
Vanguard group	3.78M	4.10%	$36.70M
Tang capital management	3.40M	3.72%	$14.25M
Fcpm iii services b.v.	2.81M	3.05%	$21.48M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Fcpm iii services b.v.	2.81M	2.97%	$21.48M
Ghost tree capital	450.00K	1.27%	$4.05M
Boxer capital management	1.18M	1.18%	$8.99M
Omega fund management	248.67K	1.17%	$1.91M
Sofinnova investments	1.81M	1.03%	$16.78M
Suvretta capital management	4.22M	0.82%	$32.30M
Sio capital management	720.04K	0.79%	$5.51M
Boxer capital	1.54M	0.73%	$13.83M
Rtw investments, lp	7.36M	0.56%	$56.28M
Tang capital management	3.40M	0.55%	$14.25M

Top Buyers

Holder	Shares	% Assets	Change
Suvretta capital management	4.22M	0.82%	4.19M
Braidwell lp	2.75M	0.34%	2.33M
Goldman sachs group	2.28M	0.00%	1.62M
Boxer capital	1.54M	0.73%	1.54M
Ecor1 capital	1.00M	0.32%	1.00M

Top Sellers

Holder	Shares	% Assets	Change
Atlas venture life science advisors	-	-	-2.10M
Adage capital partners gp	307.37K	0.00%	-1.50M
Commodore capital lp	-	-	-1.43M
Rosalind advisors	-	-	-1.41M
Camber capital management lp	-	-	-1.35M

New Positions

Holder	Shares	% Assets	Change	Value
Boxer capital	1.54M	0.73%	1.54M	$13.83M
Ecor1 capital	1.00M	0.32%	1.00M	$7.65M
Sio capital management	720.04K	0.79%	720.04K	$5.51M
Vanguard fiduciary trust	475.13K	0.00%	475.13K	$3.63M
Norges bank	459.90K	0.00%	459.90K	$4.14M

Sold Out

Holder	Change
Nelson, van denburg & campbell wealth management group	-8.00
Ifp advisors	-8.00
Srs capital advisors	-19.00
Global retirement partners	-32.00
Creative financial designs inc /adv	-33.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Mar 31, 2026	65	-64.67%	10,497,436	-86.84%	11	0.15%	32	-65.59%	18	-67.86%
Dec 31, 2025	102	-46.32%	28,686,776	-65.39%	31	0.38%	51	-52.34%	33	-31.25%
Sep 30, 2025	187	3.89%	82,873,954	6.75%	90	1.26%	105	25.00%	48	-20.00%
Jun 30, 2025	189	13.17%	80,918,624	7.29%	88	1.08%	86	-2.27%	65	35.42%
Mar 31, 2025	170	6.25%	81,976,905	5.26%	98	1.13%	88	-11.11%	49	48.48%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
US Small-Cap Growth II Equity Comp	2.41M	2.92%	-23.38K
T. Rowe Price New Horizons	2.41M	2.92%	-20.89K
State Street® SPDR® S&P® Biotech ETF	2.39M	2.89%	-24.55K
Vanguard US Total Market Shares ETF	2.02M	2.63%	478.00K
Vanguard Total Stock Mkt Idx Inv	1.85M	2.24%	-
iShares Russell 2000 ETF	1.66M	2.02%	14.05K
T. Rowe Price Integrated US Sm Gr Eq	1.60M	1.94%	-
T. Rowe Price Integrated US SmCapGrEq	1.60M	1.94%	-
Fidelity Select Biotechnology	1.51M	1.83%	-349.80K
T. Rowe Price Health Sciences	1.43M	1.73%	-91.78K

Recent Insider Transactions

Date	Name	Role	Activity	Value
Jun 01, 2026	Sarchi Christopher	Chief Commercial Officer	Sell	$110.88K
May 18, 2026	Xynos Konstantinos	Chief Medical Officer	Sell	$71.24K
May 18, 2026	Schwendenman Andrew	Chief Accounting Officer	Sell	$40.10K
May 18, 2026	Sarchi Christopher	Chief Commercial Officer	Sell	$43.82K
May 18, 2026	Astley-Sparke Philip	-	Sell	$89.70K

Insider Transactions Trends

Date	Buy	Sell
2026 Q2	-	7
2026 Q1	-	-
2025 Q4	-	4
2025 Q3	-	1
2025 Q2	-	6

REPL Ownership FAQ

Who Owns Replimune Group?

Replimune Group shareholders are primarily institutional investors at 11.39%, followed by 2.72% insiders and 85.89% retail investors. The average institutional ownership in Replimune Group's industry, Biotech Stocks , is 35.75%, which Replimune Group falls below.

Who owns the most shares of Replimune Group?

Replimune Group’s largest shareholders are Baker bros. advisors lp (11.05M shares, 11.98%), Price t rowe associates inc /md/ (8.12M shares, 8.81%), and Rtw investments, lp (7.36M shares, 7.98%). Together, they hold 28.77% of Replimune Group’s total shares outstanding.

Does Blackrock own Replimune Group?

Yes, BlackRock owns 7.08% of Replimune Group, totaling 4.71M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 42.42M$. In the last quarter, BlackRock increased its holdings by 101.23K shares, a 2.19% change.

Who is Replimune Group’s biggest shareholder by percentage of total assets invested?

Fcpm iii services b.v is Replimune Group’s biggest shareholder by percentage of total assets invested, with 2.97% of its assets in 2.81M Replimune Group shares, valued at 21.48M$.

Who is the top mutual fund holder of Replimune Group shares?

US Small-Cap Growth II Equity Comp is the top mutual fund holder of Replimune Group shares, with 2.92% of its total shares outstanding invested in 2.41M Replimune Group shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools